Multivalent nanoparticle-based vaccines protect hamsters against SARS-CoV-2 after a single immunization

Area of Science:

• Immunology
• Virology
• Nanotechnology

Background:

• The COVID-19 pandemic caused by SARS-CoV-2 continues to be a global health crisis.
• While vaccines are crucial, challenges with multiple doses and distribution persist.
• There is a need for effective, single-dose vaccine strategies against SARS-CoV-2.

Purpose of the Study:

• To develop and evaluate a novel nanoparticle-based vaccine platform for SARS-CoV-2.
• To assess the immunogenicity and protective efficacy of the engineered nanoparticles.
• To determine if a single immunization can confer protection against SARS-CoV-2 challenge.

Main Methods:

• Engineered MS2 bacteriophage coat protein to create nanoparticles.
• Displayed multiple copies of the SARS-CoV-2 spike (S) protein on the nanoparticles.
• Vaccinated Syrian hamsters with the nanoparticle vaccine.
• Assessed neutralizing antibody titers and protection against SARS-CoV-2 challenge.

Main Results:

• The nanoparticle vaccine elicited high titers of neutralizing antibodies.
• A single immunization provided complete protection in Syrian hamsters against SARS-CoV-2 challenge.
• No infectious virus was detected in the lungs of vaccinated and challenged hamsters.

Conclusions:

• The developed nanoparticle vaccine is immunogenic and protective against SARS-CoV-2 after a single dose.
• This platform offers a promising approach for rapid vaccine development against current and future pandemic threats.
• Single-dose nanoparticle vaccines may overcome challenges associated with traditional vaccine delivery.